Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Pharmacogenet Genomics. 2018 Jun;28(6):147–152. doi: 10.1097/FPC.0000000000000337

Table 2.

Top SNP from the GWAS for pCR, DFS, OS, and bevacizumab-treated patients with replication utilizing GeparQuinto

B40 GeparQuinto
rsID CHR POS CA MA N MAF OR lci uci pvalue N MAF OR lci uci Pvalue
pCR rs34843881 13 25971560 C T 914 0.096 2.899 1.940 4.331 2.04E−07 1398 0.095 0.937 0.650 1.352 0.73
DFS rs78269823 14 39264849 C T 890 0.067 0.197 0.093 0.416 5.61E−08 1398 0.117 0.952 0.688 1.316 0.76
OS rs56330643 14 100388910 A G 891 0.297 2.050 1.588 2.645 5.63E−08 1398 0.357 0.926 0.738 1.161 0.50
Bev, pCR rs7453577 6 20987675 G A 447 0.203 2.734 1.861 4.016 2.97E−07 733 0.209 1.498 1.029 2.182 0.04

rsID: reference sequence ID,